Acute myeloid leukemia (AML) with intermediate risk cytogenetics (IRcyto) comprises a variety of biological enti- ties with distinct mutational landscapes that translate into differential risks of relapse and prognosis. Optimal postremission therapy choice in this heterogeneous patient population is currently unsettled. In the current study, we...
-
September 30, 2022 (v1)PublicationUploaded on: March 24, 2023
-
September 27, 2022 (v1)Publication
Antimicrobial stewardship programs (ASPs) in hematological patients are especially relevant. However, information about ASPs in this population is scarce. For 11 years, we quarterly assessed antimicrobial consumption and incidence and death rates of multidrug-resistant (MDR) bloodstream infections (BSI) in the hematology Department. Healthcare...
Uploaded on: March 24, 2023 -
February 9, 2024 (v1)Publication
Purpose: Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated...
Uploaded on: February 11, 2024